A lot of the so called training and development at this place leaves one scratching their head. What is the program and other than a title what real training and exposure do these people get to assume new roles? Not to mention Andy could not train and or develop anybody.
That is why he will always go outside of the company and hire some poor guy or gal that was downsized in the shrinking branded world of Pharma. Also, why do they always lie to us? Ashish stated that the new products are not FDA approved as of this time. In the age of the internet why lie about this when you can go on line and see the press release from Ranbaxy in July that in fact the products did receive FDA approval. Just tell the truth to the branded sales teams at Ranbaxy and start tapping into some of the experienced people you have hired on both teams. Andy this business has passed you by. Ashish just be open and honest and give some of the talent you all hired on both teams an opportunity to take on more roles and responsibility and they will help you grow this thing. regardless start listening to the field and stop the lies.
see below:
Source: Moneycontrol.com
Share . Email . Print . A+
Ranbaxy Laboratories received US FDA approval for its new drug application for antibiotic minocycline hydrochloride extended release capsules in five strengths, reports DNA.
Ranbaxy Laboratories touched an intraday high of Rs 498.75 and an intraday low of Rs 495.70. At 09:27 hrs the share was quoting at Rs 497.95, up Rs 4.60, or 0.93%.
It was trading with volumes of 4,377 shares. In the previous trading session, the share closed up 0.72% or Rs 3.55 at Rs 493.35.
The share touched its 52-week high Rs 570 and 52-week low Rs 366.50 on 02 Aug, 2011 and 19 Dec, 2011, respectively.
Currently, it is trading -12.64% below its 52-week high and 35.87% above its 52-week low.
Market capitalisation stands at Rs 21,026.68 crore.
Set email alert for
Ranbaxy Labs